Market Newsdesk

OTTAWA, Jan. 13, 2021 (GLOBE NEWSWIRE) — CAA North & East Ontario (CAANEO) is announcing the appointment of Greater Sudbury resident Marianne Matichuk to its board of directors. The auto club provides more than 300,000 Members in the north and east Ontario region with emergency roadside service and savings through the CAA Rewards loyalty program; in addition to automotive, insurance and travel products and services.

CAANEO is part of a larger federation of eight CAA Clubs across Canada committed to providing exceptional service to more than six million members coast-to-coast; as well as advocating on issues of concern including road safety, the environment, mobility, infrastructure and consumer protection.

“Working with the dedicated team at CAANEO is truly an honour and a privilege,” says Matichuk. “I look forward to making a difference in the communities that the Club serves, and ensuring exceptional service to all of our Members.”

Matichuk has over 30 years of health and safety, political and business experience in several roles including the first elected female and former Mayor of the City of Greater Sudbury and inaugural Chief Administrative Officer of the Centre for Research in Occupational Safety and Health (CROSH).

She is a business graduate from Cambrian College, holds CRSP, CHSC, Certified Lead Auditor designations, as well as a Certified Nutrition Manager. Her integrity and balanced leadership led her to continue her inspirational work in health and safety and government relations as the Principal Consultant of M. Matichuk & Associates.

She currently serves as Chair of the Workplace Safety & Prevention Services Ontario and Board Governor of the Canadian Registered Safety Professionals; and is a Past-President of Business & Professional Women Greater Sudbury, as well as a past board member on several local charities and boards.

For her work, Marianne has received the Leadership Award of Merit from Health and Safety Ontario, Greater Sudbury Police Services Award of Appreciation, Huntington University Award of Merit and the Queen Elizabeth II Diamond Jubilee medal from the Federation of Canadian Municipalities for her service to Greater Sudbury and to all of Canada.

“We’re all very excited about Marianne’s appointment,” says Jeff Walker, President and CEO of CAANEO. “Her expertise in health and safety confirms that she truly understands the challenges and opportunities we have as a safety-focused organization. We see many opportunities ahead.”

For more information, please contact:

Jenah Thompson
Director of Marketing & Communications
CAA North & East Ontario
Phone: 613 820-1890 X 6489
Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ca4dcec2-7154-42b4-9534-87bba91cc67e

 

REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the production of two of Tate & Lyle’s newest sweeteners: DOLCIA PRIMA^® Allulose and TASTEVA^® M Stevia Sweetener.

Codexis’ latest novel enzyme products, generated in close collaboration with Tate & Lyle’s experts, will enable additional production efficiencies and further enhance Tate & Lyle’s ability to accelerate sugar and calorie reduction with best tasting, cost effective sweeteners. The new enzyme variants, which replace existing Codexis enzymes, are expected to allow Tate & Lyle to convert raw material into more finished stevia and allulose, reducing the already highly competitive cost of goods on the two products.

“TASTEVA^® M Stevia Sweetener and DOLCIA PRIMA^® Allulose are two of our most exciting new sweetener product launches, supporting our purpose of Improving Lives for Generations by allowing our customers to offer healthier food and drink choices to their consumers,” states Judith Whaley, Tate & Lyle’s Senior Vice President of Research and Development. “We are very pleased with the customer response and adoption of these new sweeteners, and are encouraged by their growing contribution to our global customers’ drive to support healthier lifestyles. Codexis has been a critical and valued partner for us throughout the development and commercialization of these two products,” adds Whaley.

“We are delighted to once again leverage our enzyme product development strengths in support of Tate & Lyle,” said John Nicols, President and CEO of Codexis. He added, “Our collaboration with Tate & Lyle is now in its seventh year and continues to be characterized by great cooperation between the two teams. We look forward to seeing Tate & Lyle continue to grow its customer base for these label-friendly sweeteners, which can play a meaningful part in addressing the critical societal health problems of diabetes and obesity.”

TASTEVA^® M Stevia Sweetener is a high-potency stevia sweetener which is more than 200 times sweeter than sugar, and is stable in processing and storage conditions over a wide pH range, making it ideal for use in low-pH systems such as beverages. The enzyme-enabled processing of stevia leaf extract gives TASTEVA^® M a competitive cost-in-use for food and beverage product formulators, providing strong end-market potential for the clean-label, sugar-replacement product.

DOLCIA PRIMA^® Allulose is a rare sugar which offers the sweet taste and functionality of sugar, but with only a fraction of the calories of sucrose and without the glycemic impact. Allulose behaves like sugar; it brings texture, browning and bulk to baking and mouthfeel to beverages and ice cream, making formulation easier for food and beverage manufacturers looking for sugar reduction solutions. Given the sugar-like functionality that allulose provides, without the calories, its use is expected to accelerate in practically any food and beverage category that conventionally employs nutritive and non-nutritive sweeteners.

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver^® technology to discover, develop and commercialize proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and food ingredients, industrial enzymes, enzymes for use in molecular biology, diagnostics and other life science applications, and enzymes and other proteins as biotherapeutics. Codexis’ proven technology platform delivers value by enabling highly targeted and application-relevant improvements in protein performance. For more information, see www.codexis.com.

About Tate & Lyle

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle’s purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totaled £2.9 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or Linkedin.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, including Codexis’ expectations regarding its commercial relationship with Tate & Lyle and prospects for the novel enzyme products, including anticipated production efficiencies and cost reduction, they are forward-looking statements reflecting the current beliefs and expectations of Codexis’ management. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers; and potential adverse effects to Codexis’ business if its products are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2020 and Form 10-Q filed with the SEC on November 6, 2020, including under the caption “Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Codexis Contact:

Argot Partners
Stephanie Marks/Natallia Clancy
[email protected]
(212) 600-1902

Tate & Lyle Contact:

Carolyn Tyler, Global Communications Manager
[email protected]
Cell: +44 (0)7584 774 808

NORWALK, Conn., Jan. 13, 2021 (GLOBE NEWSWIRE) — Reed’s Inc. (Nasdaq: REED), owner of the nation’s leading portfolio of handcrafted, all-natural beverages, today announced preliminary unaudited revenue results for the fiscal fourth quarter and full year 2020 ended December 31, 2020.

Reed anticipates nets sales for the fourth quarter of 2020 to be approximately $10.3 million, representing growth of 44% year-over-year and 22% sequentially over the previous quarter. For the full year of 2020, Reed’s anticipates net sales to be approximately $41.3 million, a increase of 22% compared to $33.8 million for the full year of 2019. These figures are preliminary and unaudited, and actual revenues may differ.

“We are pleased to report continued net sales growth representing positive momentum across all channels,” stated Norman E. Snyder, Chief Executive Officer of Reed’s, Inc. “Despite the challenges we have navigated in the face of the pandemic this year, these results demonstrate the continued support for the Reed’s brand and the future opportunities that lie ahead.”

About Reed’s, Inc.

Established in 1989, Reed’s® is America’s number 1 name in Ginger and America’s best-selling Ginger Beer brand and innovator for decades. Virgil’s™ is America’s best-selling independent, full line of natural craft sodas. The Reed’s® portfolio is sold in over 40,000 retail doors nationwide. Reed’s core product line of Original, Extra and Strongest Craft Ginger Beers, along with the Certified Ketogenic Zero Sugar Extra Ginger Beer are unique due to the proprietary process of using fresh ginger root combined with a Jamaican inspired recipe of natural spices and fruit juices. The company uses this same handcrafted approach in its award-winning Virgil’s™ line of great tasting, bold flavored craft sodas and Certified Ketogenic Zero Sugar Varieties.

For more information about Reed’s, please visit the Company’s website at: http://www.drinkreeds.com or call 800-99-REEDS. Follow Reed’s on Twitter, Instagram, and Facebook @drinkreeds.

For more information about Virgil’s, please visit Virgil’s website at: http://www.virgils.com. Follow Virgil’s on Twitter and Instagram @drinkvirgils and on Facebook @drinkvirgilssoda.

Forward-Looking Statements

Some portions of this press release, particularly those describing Reed’s goals and strategies, contain “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe future plans, objectives or goals are also forward-looking statements. While Reed’s is working to achieve those goals and strategies, actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These risks and uncertainties include difficulty in marketing its products and services, maintaining and protecting brand recognition, the need for significant capital, dependence on third party distributors, dependence on third party brewers, increasing costs of fuel and freight, protection of intellectual property, competition and other factors, any of which could have an adverse effect on the business plans of Reed’s, its reputation in the industry or its expected financial return from operations and results of operations. In light of significant risks and uncertainties inherent in forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by Reed’s that they will achieve such forward-looking statements. For further details, please see our most recent reports on Form 10-K and Form 10-Q, as filed with the Securities and Exchange Commission, as they may be amended from time to time. Reed’s undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Cautionary Note Regarding Preliminary Financial Information, Financial Guidance and Growth

Preliminary financial information, financial guidance and growth disclosure should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Estimated preliminary results are subject to completion of our customary quarterly and annual financial closing and audit and review procedures and are not comprehensive statements of our financial results for the three months and fiscal year ended December 31, 2020 and are subject to adjustments as a result of such procedures. In addition, preliminary financial information and accelerated growth disclosure is not necessarily indicative of the results to be achieved in any future period. Our financial statements and related notes as of and for the fiscal year ended December 31, 2020 is expected to be filed with the SEC during March of 2021.

CONTACTS:

Investor Relations
Scott Van Winkle, ICR
(800) 997-3337 Ext 2
Or (617) 956-6736
Email: [email protected]
www.reedsinc.com

 

Press release

Synairgen plc

(‘Synairgen’ or the ‘Company’)

Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients

Southampton, UK – 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.

As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is deemed an Urgent Public Health study by the UK’s National Institute for Health Research (NIHR). In the US, SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA).  The Company is seeking further equivalent prioritisations and support from governments in participating countries.

Synairgen’s SG018 trial is a randomised placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. After reporting the results for the primary and key secondary endpoints of the study, enrolled patients will continue to be assessed for long-COVID-19 symptoms. 

Richard Marsden, CEO of Synairgen, commented:
“We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective. We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis.”

Synairgen is also running an ongoing Phase II trial of inhaled interferon beta in non-hospitalised ‘at risk’ patients, (SG016), that is progressing rapidly. For more information and to take part, visit www.covidtrialathome.com.

This announcement contains inside information as contained in Article 7 of the Market Abuse Regulation No. 596/2014 (‘MAR’).

-ENDS-

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and joint broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith
Tel: +44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Olivia Manser, Carina Jurs
[email protected]
Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.  Synairgen is currently fully focused on progressing its inhaled interferon beta broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. 

Synairgen’s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

SNG001 (inhaled Interferon beta) applicability to COVID-19

Interferon beta (‘IFN-beta’) is a naturally-occurring protein, which orchestrates the body’s antiviral responses. It is used widely in the treatment of multiple sclerosis and is a safe and well tolerated drug. There is growing evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in ‘at-risk’ patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2, have evolved mechanisms which suppress endogenous IFN-beta production, helping the virus to evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells in vitro either prevents or greatly reduces viral replication, potentially reducing the severity of infection and accelerating recovery. Synairgen’s SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action. Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date.

In July 2020, Synairgen announced the results of its Phase II double-blind, placebo-controlled study of 101 randomised COVID-19 hospitalised patients, which showed that SNG001 given for 14 days was associated with greater odds of improvement versus placebo on the WHO Ordinal Scale for Clinical Improvement and more rapid recovery to the point where patients were no longer limited in their activity, with a greater proportion of patients recovering during the 28-day study period.

The results were published in The Lancet Respiratory Medicine: “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”. Monk, P D PhD, et al., 12 November 2020, accessible here.

2020 Growth, led by Wearable Universal Contact Tracing, is powering sales of its core Smart Facilities Solutions

PHILADELPHIA, Jan. 13, 2021 (GLOBE NEWSWIRE) — Microshare announced an expansion of its executive leadership team, building on 2020’s record revenue growth and global expansion.

“Providing our solutions at scale and in all geographies has been a strategic goal from day one at Microshare,” says Microshare CEO Ron Rock. “With our IoT data solutions now deployed on five continents and our revenue growing robustly, the addition of these four world class talents is perfectly timed to take Microshare to the next level.”

Microshare ended 2020 with tremendous growth, driven in part by its innovative Universal Contact Tracing (UCT) solution, which is now deployed in factories, offices and other facilities around the world for such clients as Glaxo-SmithKline and Rent-A-Center. Because all of Microshare’s Smart Facilities solutions run on the LoRaWan Network optimized for Microsoft’s Azure IoT, many new clients have chosen to add additional capabilities like Indoor Air Quality Monitoring, Asset Zoning, Predictive Cleaning and Occupancy Monitoring on top of Microshare’s innovative pandemic-related solutions.

“This new talent will help us scale, position us for continued international market success and prepare Microshare for B Round financing in 2021,” says Charles Paumelle, Managing Director for UK and EMEA. “Each of my new colleagues has experience in managing the challenges of moving early stage companies to maturity and excelling at the global level.”

Joining as of January are Phil Adams as Executive Vice President of Strategic Operations; Lauren Miller as Chief Financial Officer; Nadine North as Chief People & Wellness Officer, and Michael Moran as Chief Marketing Officer and Director of Risk & Sustainability.

• 
  EVP Phil Adams
  is charged with implementing repeatable, scalable business processes and attracting growth capital. As CEO of World Energy, a pioneering B2B eProcurement firm, Adams grew World Energy from seven employees to 130, took it public and had a successful exit to a strategic acquirer.
• 
  CFO Lauren Miller
  is a veteran of multinational finance, including posts at Paramount, Warner Bros. and JP Morgan Chase, She was most recently Chief Financial Officer of Iroko Ltd, often referred to as the “Netflix of Africa,” which Miller helped steward from a start-up to one of Africa’s largest media companies, as well as a successful sale.
• 
  Nadine North
  , Chief People and Wellness Officer, will lead efforts to attract talent and, in her Wellness role, help shape Microshare’s focus on healthy work environments enabled by data. Previously, she helped manage expansion plans for Siebel Systems, from $300m to $1.5b, from 800 people to over 8000, and into over 25 countries, before its 2005 purchase by Oracle.
• 
  Michael Moran
  joins as CMO and Director of Risk & Sustainability to manage Microshare’s global brand, marketing and thought leadership. Moran has held senior positions at Roubini Global Economics, Renaissance Capital, the Council on Foreign Relations, and a host of major journalistic outlets. Most recently, he was a Partner and Chief US/Macro Analyst at the global advisory Control Risks.

Media Inquiries: Simon Redgate [email protected] | +44 (0)7850 112703

About Microshare

Microshare^® provides turnkey Smart Facilities data solutions at scale that bring safety, wellness, cost savings and sustainability to our clients’ vital assets. Our Sensing-as-a-Service model and global reseller network helped our clients get back to business quickly, safely and cost efficiently in 2020, all while shedding new light on the true performance and utility of their real estate holdings to prepare them for success in the post-pandemic future. Microshare is a leader in LoRaWAN applications and a proud member of the LoRa Alliance^®. www.microshare.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7d021abf-5e3e-41e8-a1a8-dc0d81ffe706

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that it produced a total of 19,958 ounces of gold in December 2020 bringing the total for the fourth quarter of 2020 to 57,265 ounces compared with 65,237 ounces in the fourth quarter of 2019. For the full year, the Company produced a total of 220,194 ounces of gold in 2020 which is within its annual guidance range of between 218,000 and 226,000 ounces. 2020 was the fifth consecutive year that the Company has met or exceeded its annual production guidance. The Company produced a total of 239,991 ounces of gold in 2019.

Lombardo Paredes, Chief Executive Officer of Gran Colombia, commenting on the Company’s latest results, said, “Our Segovia Operations had another steady quarter, finishing the year within guidance as expected. We have now produced a total of approximately 1.3 million ounces of gold from Segovia in the 10 years since we acquired the mining title and the head grade has averaged 13.8 g/t over that period of time, establishing Segovia as one of the highest-grade underground global gold mines, as further evidenced by the recently announced high-grade intercepts from our ongoing drilling program. In the fourth quarter of 2020, we continued the ongoing development of our mines at Segovia and in December, we commenced production activities at our fourth mine, Carla, which is expected to ramp up further during the first half of 2021. In the fourth quarter of 2020, we used our free cash flow to fund investments in private placements completed by Caldas Gold and ESV Resources in the amount of CA$17 million and CA$3 million, respectively, to fund the repurchases of 484,100 common shares for cancellation at a cost of approximately CA$2.9 million, to pay dividends totaling CA$1.9 million to our shareholders and to fund the principal and interest payments on our debt of approximately US$5.5 million. At the end of December 2020, Gran Colombia had a cash position of approximately US$90 million.”

“The Marmato Operations continued to gain momentum in the fourth quarter of 2020 with the implementation of the optimized mine plan in the existing upper mining operations and commencement of the planned plant expansion to be completed in the third quarter of 2021. Preparatory activities are underway related to the expansion of underground mining operations into the Marmato Deep Zone (“MDZ”) as Caldas Gold awaits the extension of its Marmato mining title, expected to be completed later this month. Caldas Gold is also currently working closely with the management of Aris Gold to prepare for a smooth transition to the new board and management of Caldas Gold once the title extension is completed. At that time, Gran Colombia’s interest in the new “Aris Gold Corporation” will be approximately 44.3% on an undiluted basis.”

The Segovia Operations processed an average of 1,328 tonnes per day (“tpd”) in December 2020 with an average head grade of 14.7 g/t resulting in gold production of 17,438 ounces in the month. This brought Segovia’s total production for the fourth quarter of 2020 to 50,084 ounces compared with 58,180 ounces in the fourth quarter of 2019. For the full year, the Segovia Operations produced a total of 196,362 ounces of gold in 2020 which is within its annual guidance range of between 195,000 and 200,000 ounces. Segovia produced 214,241 ounces of gold in 2019. Overall, the Segovia Operations processed an average of 1,280 tpd in 2020 at an average head grade of 14.5 g/t compared with 1,237 tpd at an average head grade of 16.4 g/t last year. Gold production from the four Company mines represented approximately 88% of Segovia’s total production in 2020. The other 12% of Segovia’s gold production in 2020 was sourced from the small mines operating in the regional area within the Segovia mining title under contract with the Company as part of its ESG initiatives. The Company currently has 55 small mines under contract and, in 2020, the Company saw a 10% increase in material from the small mines. In addition, head grades in 2020 in the material from the small mines also improved to an average of 8.5 g/t, up from 6.8 g/t last year, reaching an average of 11.8 g/t in the fourth quarter of 2020, driven by material from a small mine operating near the Cristales vein, an area the Company will commence drilling in February 2021 as part of its regional drilling campaign, which delivered approximately 1,300 tonnes of material at an average head grade of 47 g/t.  

At Caldas Gold’s Marmato mine, the plant processed an average of 1,075 tpd in December at an average head grade of 2.7 g/t resulting in gold production of 2,520 ounces. This brought Marmato’s total gold production for the fourth quarter of 2020 to 7,181 ounces compared with 7,057 ounces in the fourth quarter last year.  For the full year, Marmato produced 23,832 ounces of gold in 2020 which is within its annual guidance range of between 23,000 and 26,000 ounces. The Marmato mine produced 25,750 ounces in 2019.

Gran Colombia expects to release its 2020 fourth quarter and annual financial results together with the updated mineral reserve and resource estimates for its Segovia Operations on or about March 31, 2021. Webcast details will be announced in early March.

About Gran Colombia Gold Corp.

Gran Colombia is a Canadian-based mid-tier gold producer with its primary focus in Colombia where it is currently the largest underground gold and silver producer with several mines in operation at its high-grade Segovia Operations. Gran Colombia owns approximately 53.5% of Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF), a Canadian mining company currently advancing a major expansion and modernization of its underground mining operations at its Marmato Project in Colombia. Gran Colombia’s project pipeline includes its Zancudo Project in Colombia, currently in the process of being spun out to ESV Resources Ltd. (TSX-V: ESV.H) together with an approximately 18% equity interest in Gold X Mining Corp. (TSXV: GLDX) (Guyana – Toroparu) and an approximately 26% equity interest in Western Atlas Resources Inc. (“Western Atlas”) (TSX-V: WA) (Nunavut – Meadowbank).

Additional information on Gran Colombia can be found on its website at www.grancolombiagold.com and by reviewing its profile on SEDAR at www.sedar.com.

Cautionary Statement on Forward-Looking Information:

This news release contains “forward-looking information”, which may include, but is not limited to, statements with respect to production, the Marmato mining title extension and timing thereof, closing of the Aris Gold transaction and anticipated business plans or strategies. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Gran Colombia to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in the Company’s Annual Information Form dated as of March 30, 2020 which is available for view on SEDAR at www.sedar.com. Forward-looking statements contained herein are made as of the date of this press release and Gran Colombia disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

For Further Information, Contact:

Mike Davies
Chief Financial Officer
(416) 360-4653
[email protected]

Company’s second-generation aligners engineered to make teeth straightening more comfortable and tooth movement more predictable

Groundbreaking technology enables precision-cut aligners with graduated thicknesses

NASHVILLE, Tenn., Jan. 13, 2021 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today introduced SmileDirectClub Aligners with Comfort Sense™ technology, designed to make clear aligner treatment more comfortable and tooth movement more predictable. This Smile Advancement is one of the Company’s numerous telehealth innovations and patents driving the future of oral care.

Comfort Sense technology features the Company’s patented laser technology that precision-cuts aligners for a smoother fit, which, combined with the variable thicknesses of the aligners and doctor-prescribed and monitored treatment plans that start with lighter movements to ease customers into treatment all result in a more comfortable fit and treatment for customers from start to finish. Comfort Sense technology will be used in all SmileDirectClub Aligners and Nighttime Aligners. All SmileDirectClub Aligners are made of BPA-free materials and have a matte finish to match the appearance of natural teeth.

“One of the primary concerns people have when considering whether to straighten their teeth is if the process will be uncomfortable or painful,” said Dr. Jeffrey Sulitzer, Chief Clinical Officer, SmileDirectClub. “The Comfort Sense technology used to manufacture our aligners helps ease customers into treatment more comfortably by using a next generation of laser technology and by gradually increasing the thickness of the aligner to safely and gently move teeth. This makes it easier for patients to follow the wear requirements of their doctor-prescribed treatment plans and get the smile they’ve always wanted.”

SmileDirectClub is the largest vertically integrated clear aligner company that manufactures all of its aligners in the U.S. The company’s state-of-the-art FDA-certified and registered Tennessee manufacturing facility features one of the largest fleets of 3D printers in North America. SmileDirectClub’s aligner system is specifically designed for treatment using its groundbreaking telehealth platform, delivering an innovative method for safely and gently straightening smiles without needing buttons, attachments or teeth filings. Thanks to advancements in its second-generation manufacturing technology, SmileDirectClub is now able to produce aligners more efficiently and with greater precision than ever before.

“SmileDirectClub pioneered the future of teeth straightening by creating the first telehealth solution for giving customers a smile they love,” said Josh Chapman, Chief Brand Officer, SmileDirectClub. “With the introduction of our Comfort Sense technology, not only is SmileDirectClub more accessible, affordable and convenient than other options, but we also make one of the most advanced and comfortable aligners in the world.”

Since launching in the U.S. in 2014, SmileDirectClub has become one of the fastest-growing health technology companies and continues to be the leading telehealth platform for orthodontia, serving well over one million customers around the world.

About SmileDirectClub

SmileDirectClub, Inc. (Nasdaq: SDC) (“SmileDirectClub”) is an oral care company and creator of the first medtech platform for teeth straightening. Through its cutting-edge telehealth technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry, from clear aligner therapy to its affordable, premium oral care products line. SmileDirectClub’s mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Germany, Austria, Hong Kong, Singapore and Spain. For more information, please visit SmileDirectClub.com.

Contact:
SmileDirectClub Media Relations: [email protected]

SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — The RealReal (Nasdaq: REAL)–the world’s largest online marketplace for authenticated, consigned luxury goods–today released its 2021 Luxury Consignment Report. The report charts the top 2020 trends and shifts impacting luxury resale value, which The RealReal determines based on advanced technology, its real-time pricing algorithm that factors up to 50 attributes per item across ~16 million items sold, and human expertise.

Despite the unpredictable fluctuations of 2020, more people adopted consignment than ever before — especially Gen Z and Millennials, who represented 35% of new consignors. Consignors helped make fashion more sustainable by keeping pieces in circulation, with the average consignor saving the equivalent of 4,333 glasses of water.

“The pandemic has had a lasting impact on the resale market and, through the challenges of the past year, we’re seeing a mindset shift among our ~20 million members towards investing in, and living by, what we truly value,” said Rati Levesque, COO of The RealReal. “Investment pieces, the new capsule wardrobe essentials, and late ‘90s to early ‘00s vintage are the top trends yielding rising returns to sellers. As we enter a new year, the record numbers of consignors joining the circular economy are a bright spot paving the way to a more sustainable fashion future.”

Consignment trends that rose to the top in 2020:

• Goyard topped the list of the top 10 luxury brands
  • Patek Philippe rose most in the ranking of brands with the greatest resale value – up three spots from last year
• Demand for high-value bags skyrocketed
  • Average selling price rose up to 80% for in-demand styles
• Gucci was #1 in vintage
  • Resale value grew another 12%
• Rolex strengthened lead as #1 watch brand
  • 5 of top 10 men’s watches with greatest resale value growth were Rolex
• Capsule wardrobe essential were redefined
  • Gender-fluid staples including puffer coats and waist bags dominated

To see the top luxury consignment trends of 2020 and learn more about how consignors can earn the most in 2021, view The RealReal’s 2021 Luxury Consignment Report.

About The RealReal Inc.

The RealReal is the world’s largest online marketplace for authenticated, consigned luxury goods. With a rigorous authentication process overseen by experts, The RealReal provides a safe and reliable platform for consumers to buy and sell their luxury items. We have 150+ in-house gemologists, horologists and brand authenticators who inspect thousands of items each day. As a sustainable company, we give new life to pieces by hundreds of brands, from Gucci to Cartier, supporting the circular economy. We make consigning effortless with free in-home pickup, drop-off service, virtual appointments and direct shipping for individual consignors and estates. At our stores in Chicago, Los Angeles, New York City, Palo Alto and San Francisco, customers can shop, consign, and meet with our experts. At our 11 Luxury Consignment Offices, six of which are in our retail stores, our expert staff provides free valuations.

Press Contact:
Christine Heerwagen
[email protected]

PORTLAND, Ore., Jan. 13, 2021 (GLOBE NEWSWIRE) — Indelible LLC, a leading cybersecurity firm helping clients solve some of the most complex IT security challenges, announced the company has gathered significant information on a malfeasant push notification campaign operating across more than 100 domains. The “PushBug” campaign is a highly resilient operation, spread across numerous domains and installing browser-based activity that is difficult to detect.

Users browsing certain websites including “free” movie websites, get presented with a message to “Allow” notifications from the website to view the content, however that is not what happens on the system. Once the user clicks “Allow” the website installs a service worker in the user’s browser which begins to interact with malfeasant domains involved in tracking user activity and giving the malfeasant operators the ability to create social engineering pop-up notification attacks at will. For more information, please download PushBug: Uncovering a Large Scale RFC 8030 API Abuse Campaign at https://bit.ly/2Xy4FgT.

Detection to date has been most fruitful from Threat Hunting by the Indelible mSOC™ (Managed Security Operations Center) team, recognizing suspicious activity using human and machine learning techniques. Indelible has collected enough tracking and telemetry evidence to be concerned that systems impacted by PushBug can be identified through their external IP, unique identifiers, and user agents.

In investigating this activity, new forensic techniques were developed by the Indelible mSOC™ team. “While we have some of the most accomplished and experienced individuals in the cybersecurity field, once this was detected we were unified in our desire to solve this— a real credit to the collaboration of our team,” said David Bell, Senior Vice President of Business Development.

In addition, the research shows that the operation is growing in size, designed to thwart blocking of domain names, and remains undetected through legitimate RFC/API abuse. The notifications pushed to a user’s browser include fake antivirus infection messages, dating notices, uranium investment notices, and links that contain multiple redirectors.

“The potential for using this technique for purposes beyond what is happening now presents a level of risk for further social engineering,” said Frank Angiolelli, Vice President of Security at Indelible. “To date, Google’s Chrome appears to be the only browser impacted, where the preferences file is modified to include new entries. We have notified Google and their response has been to take our report seriously and investigate.”

About Indelible

Indelible LLC provides advanced cybersecurity services to both advise on, and directly manage security posture and active cyber threats. Combining strategic and tactical guidance on capability and program alongside a highly competitive Cyber Incident Response (IR) offering, Indelible can help with asserting control over the impact of a cyber incident or raise the chances of avoiding a high-impact incident altogether. For more information about Indelible and its products visit: www.Indelible.global.

For more information, contact:
Betsey Rogers
Public Relations
BridgeView Marketing
603-821-0809
[email protected] 

 

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider and industry-leading provider of high-performance, jet-powered unmanned aerial systems, announced today that Kratos has received an additional order from a long-term international customer for 20 high-performance jet drones and support equipment to satisfy their continuing current and future missions and operations.

Steve Fendley, President of Kratos’ Unmanned Systems Division, said, “Over the last three years, in anticipation of future drone orders, Kratos ramped up production line rates on several of our drone systems so that we would have a constant rate of aircraft coming off the production line to meet not only contracted but also future demand. In most cases, our orders are now exceeding our initial production rates as a result of our increase in orders. This is great news for our company and our personnel as we have established such a substantial backlog of production orders and are now increasing our production rates even further. We appreciate our customers’ confidence in our systems and our ability to deliver within the often-tight schedules. Importantly, these international orders help our production economies-of-scale enabling us to retain our low-cost benchmarks for all our customers including international and across the U.S. Government.”

Due to competitive, customer-related, and other considerations, no additional information will be provided related to this new contract award.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, please visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2019, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:

Yolanda White
858-812-7302 Direct

Investor Information:

877-934-4687
[email protected]